Document:

Exhibit 10.4

 

NEITHER THE ISSUANCE
AND SALE OF THE SECURITIES REPRESENTED BY THIS DOCUMENT NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED
FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER
THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER AND REASONABLY
APPROVED BY THE COMPANY), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD
PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH
A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES. 

 

CONVERTIBLE
PROMISSORY NOTE 

 

November ___, 2014

 

$————.00

 

FOR VALUE RECEIVED,
NuGene, Inc., a California corporation (the “Company”), hereby promises to pay to the order of _______________________________,
or its successors or assigns ( the “Holder”), the principal amount of ———————
and 00/100 United States Dollars (US$—————.00) on or prior to the date that is 180 days after
the date hereof or such earlier or later date as is set forth in the Subscription Agreement defined below (the “Maturity
Date”), and to pay interest on the unpaid principal balance hereof at the six month London Interbank Offered Rate (LIBOR),
plus one percent per annum (the “Applicable Rate”) calculated at and commencing as of the date the proceeds
hereunder are funded to the Company (the “Funding Date”), in accordance with the terms hereof. This Convertible
Promissory Note (this note, and all modifications, extensions, future advances, supplements, and renewals thereof, and any substitutions
therefor, hereinafter referred to as the “Note”) shall be payable in accordance with the terms set forth below.
This Note is one of several notes in the aggregate principal amount of $375,000, and the “Note” referenced in that
certain Subscription Agreement executed on the date hereof by and between the Company and the Holder (the “Subscription
Agreement”). This Note is subject to the terms and conditions contained in the Subscription Agreement and, notwithstanding
anything herein to the contrary, the terms of the Subscription Agreement shall in all respects govern and supersede over the terms
of this Note. Any term not defined herein shall have the meaning set forth in the Subscription Agreement.

 

    	1

    	 

    

 

1.           Payments
of Principal and Interest.

 

(a)          Payment
of Principal. The principal amount of this Note shall be paid to the Holder on or prior to the Maturity Date.

 

(b)          Payment
of Interest. Interest on the unpaid principal balance of this Note shall accrue at the Applicable Rate commencing on the Funding
Date. Interest shall be computed on the basis of a 365-day year and paid for the actual number of days elapsed. Accrued and unpaid
interest under this Note shall be paid in full on the Maturity Date. Any accrued but unpaid interest shall be converted as set
forth herein.

 

(c)          Payment
of Default Interest. Any amount of principal or interest on this Note which is not paid when due shall bear interest from the
date due until such past due amount is paid at a rate of interest equal to the Applicable Rate plus five percent (5%) per annum
(the “Default Rate”).

 

(d)          General
Payment Provisions. All payments of principal and interest on this Note shall be made in lawful money of the United States
of America by certified bank check or wire transfer to such account as the Holder may designate by written notice to the Company
in accordance with the provisions of this Note. Whenever any amount expressed to be due by the terms of this Note is due on any
day which is not a Business Day, the same shall instead be due on the next succeeding Business Day. For purposes of this Note,
“Business Day” shall mean any day other than a Saturday, Sunday or a day on which commercial banks in the State of
California are authorized or required by law or executive order to remain closed.

 

(e)          Prepayment.
At any time prior to the Maturity Date and/or the Conversion Date, the Company may pre-pay this Note in full or in part without
penalty. Upon prepayment of this Note in full, the Holder shall have no further rights under this Note (except for such rights
that may specifically survive the payment of the Note), including no rights of conversion.

 

2. Conversion of
Note.

 

(a)          Mandatory
Conversion. The unpaid principal and accrued and unpaid interest on the Note shall automatically convert into shares of common
stock of NewcoNG (the “NewcoNg Common Stock”) upon the consummation of the issuance and sale by the Company
of Common Stock pursuant to the Placement so that together with the proceeds to the Company from the Notes, the Company receives
or will have received on aggregate of $2,000,000 in equity capital. The conversion price per share of NewcoNg Common Stock
shall be equal to the price per share in the Placement. The number of shares into which the Note is convertible are referred to
herein as the “Conversion Shares”. The Company shall notify the Holder in writing of the consummation of the
Placement and within two (2) Business Days after consummation of the Placement (the “Closing”), the Company
shall instruct its transfer agent to issue and surrender to a nationally recognized overnight courier for delivery to the address
specified by Holder, a certificate, registered in the name of the Holder, for the number of Conversion Shares to which the Holder
shall be entitled.

 

    	2

    	 

    

 

 

(1)         Record
Holder. The person or persons entitled to receive the shares of NewcoNg Common Stock issuable upon a conversion of this
Note shall be treated for all purposes as the record holder(s) of such shares of NewcoNg Common Stock as of the Conversion
Date.

 

(2)         Transfer
Taxes. The issuance of certificates for shares of the NewcoNg Common Stock on conversion of this Note shall be made
without charge to the Holder hereof for any documentary stamp or similar taxes, or any other issuance or transfer fees of any nature
or kind that may be payable in respect of the issue or delivery of such certificates, any such taxes or fees, if payable, to be
paid by the Company.

 

(b)          Adjustments
to Conversion Price. If, at any time while this Note is outstanding other than a transaction with NewcoNG: (i) the Company
effects any merger or consolidation or business combination of the Company with or into another Person, (ii) the Company effects
any sale of all or substantially all of its assets in one transaction or a series of related transactions, (iii) any tender offer
or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted
to tender or exchange their shares for other securities, cash or property, or (iv) the Company effects any reclassification of
the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged
for other securities, cash or property (in any such case, a “Fundamental Transaction”), then upon any subsequent
conversion of this Note, the Holder shall have the right to receive, for each Conversion Share that would have been issuable upon
such conversion immediately prior to the occurrence of such Fundamental Transaction, the same kind and amount of securities, cash
or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately
prior to such Fundamental Transaction, the holder of one (1) share of Common Stock (the “Alternate Consideration”).
For purposes of any such conversion, the determination of the Conversion Price shall be appropriately adjusted to apply to such
Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one (1) share of Common Stock in
such Fundamental Transaction, and the Company shall apportion the Conversion Price among the Alternate Consideration in a reasonable
manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are
given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given
the same choice as to the Alternate Consideration it receives upon any conversion of this Note following such Fundamental Transaction.
To the extent necessary to effectuate the foregoing provisions, any successor to the Company or surviving entity in such Fundamental
Transaction shall issue to the Holder a new note consistent with the foregoing provisions and evidencing the Holder’s right
to convert such note into Alternate Consideration. The terms of any agreement pursuant to which a Fundamental Transaction is effected
shall include terms requiring any such successor or surviving entity to comply with the provisions of this Section and insuring
that this Note (or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous to a Fundamental
Transaction.

 

    	3

    	 

    

 

3.           Voting
Rights. The Holder shall have no voting rights under this Note, except as required by applicable law, and as expressly provided
in this Note.

 

4.           Defaults
and Remedies.

 

(a)          Events
of Default. The occurrence of any of the following events shall constitute an “Event of Default” hereunder:
(i) the Company shall fail to pay any installment of interest, principal or other sums due under this Note within ten (10) business
days of when any such payment shall be due and payable; (ii) the Company makes an assignment for the benefit of creditors; (iii)
any order or decree is rendered by a court which appoints or requires the appointment of a receiver, liquidator or trustee for
the Company, and the order or decree is not vacated within sixty (60) days from the date of entry thereof; (iv) any order or decree
is rendered by a court adjudicating the Company insolvent, and the order or decree is not vacated within sixty (60) days from the
date of entry thereof; (v) the Company files a petition in bankruptcy under the provisions of any bankruptcy law or any insolvency
act; (vi) the Company admits, in writing, its inability to pay its debts as they become due (provided, however, that receipt by
the Company of an audit letter from its accountants questioning the viability of the Company as a going concern shall not, in and
of itself, be construed as an admission by the Company of its inability to pay its debts as they become due); (vii) a proceeding
or petition in bankruptcy is filed against the Company and such proceeding or petition is not dismissed within ninety (90) days
from the date it is filed; (viii) the Company files a petition or answer seeking reorganization or arrangement under the bankruptcy
laws or any law or statute of the United States or any other foreign country or state; (ix) the Company fails to enter into
a license agreement with kathy ireland WorldWide, Inc.; or (x) the Company shall fail to perform, comply with or abide by any
of the stipulations, agreements, conditions and/or covenants contained in this Note on the part of the Company to be performed
complied with or abided by, and such failure is not cured within thirty (30) days after written notice of such failure is delivered
by Holder to the Company.

 

(b)          Remedies.
Upon the occurrence of one or more Events of Default, the Holder, at its option and without further notice, demand or presentment
for payment to the Company or others, may declare the then outstanding principal balance of this Note, together with all other
sums due under the Note, immediately due and payable, together with all accrued and unpaid interest thereon and thereafter all
such sums shall bear interest at the Default Rate, together with all reasonable attorneys’ fees, paralegals’ fees and
costs and expenses incurred by the Holder in collecting or enforcing payment thereof (whether such reasonable fees, costs or expenses
are incurred in negotiations, all trial and appellate levels, administrative proceedings, bankruptcy proceedings or otherwise),
and all other sums due by the Company hereunder, all without any relief whatsoever from any valuation or appraisement laws and
payment thereof may be enforced and recovered in whole or in part at any time by one or more of the remedies provided to the Holder
at law, in equity, or under this Note.

 

    	4

    	 

    

 

6.           Lost
or Stolen Note. Upon notice to the Company of the loss, theft, destruction or mutilation of this Note, and, in the case of
loss, theft or destruction, of an indemnification undertaking by the Holder to the Company in a form reasonably acceptable to the
Company and customary for similar circumstances in commercial lender/borrower circumstances, and, in the case of mutilation, upon
surrender and cancellation of the Note, the Company shall execute and deliver a new Note of like tenor and date and in substantially
the same form as this Note; provided, however, the Company shall not be obligated to re-issue a Note if the Holder contemporaneously
requests the Company to convert such remaining principal amount and interest into Common Stock.

 

7.           Cancellation.
After all principal, accrued interest and all other sums at any time owed on this Note have been paid in full, this Note shall
automatically be deemed canceled, shall be surrendered to the Company for cancellation and shall not be re-issued.

 

8.           Governing
Law. This Note shall be construed and enforced in accordance with, and all questions concerning the construction, validity,
interpretation and performance of this Note shall be governed by, the laws of the State of California, without giving effect to
provisions thereof regarding conflict of laws. Each party hereto hereby irrevocably submits to the non-exclusive jurisdiction of
the state and federal courts sitting in the State of California for the adjudication of any dispute hereunder or in connection
herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert
in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such
suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper,
provided, however, nothing contained herein shall limit the Holder’s ability to bring suit or enforce this Note in any other
jurisdiction. Each party hereto hereby irrevocably waives personal service of process and consents to process being served in any
such suit, action or proceeding by sending by certified mail or overnight courier a copy thereof to such party at the address indicated
in the preamble hereto and agrees that such service shall constitute good and sufficient service of process and notice thereof.
Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH
PARTY HERETO HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY
DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS NOTE OR ANY TRANSACTION CONTEMPLATED HEREBY. 

 

9.           Remedies,
Characterizations, Other Obligations, Breaches and Injunctive Relief. The remedies of the Holder as provided herein shall be
cumulative and concurrent and may be pursued singly, successively or together, at the sole discretion of the Holder, and may be
exercised as often as occasion therefor shall occur; and the failure to exercise any such right or remedy shall in no event be
construed as a waiver or release thereof.

 

10.          Specific
Shall Not Limit General; Construction. No specific provision contained in this Note shall limit or modify any more general
provision contained herein. This Note shall be deemed to be jointly drafted by the Company and the Holder and shall not be construed
against any person as the drafter hereof.

 

    	5

    	 

    

 

11.          Failure
or Indulgence Not Waiver. Holder shall not be deemed, by any act of omission or commission, to have waived any of its rights
or remedies hereunder, unless such waiver is in writing and signed by Holder, and then only to the extent specifically set forth
in the writing. A waiver on one event shall not be construed as continuing or as a bar to or waiver of any right or remedy to a
subsequent event.

 

12.          Notice.
Notice shall be given to each party at the address indicated in the preamble hereto or at such other address as provided to the
other party in writing.

 

13.          Usury
Savings Clause. Notwithstanding any provision in this Note, the total liability for payments of interest and payments in the
nature of interest, including, without limitation, all charges, fees, exactions, or other sums which may at any time be deemed
to be interest, shall not exceed the limit imposed by the usury laws of the jurisdiction governing this Note or any other applicable
law. In the event the total liability of payments of interest and payments in the nature of interest, including, without limitation,
all charges, fees, exactions or other sums which may at any time be deemed to be interest, shall, for any reason whatsoever, result
in an effective rate of interest, which for any month or other interest payment period exceeds the limit imposed by the usury laws
of the jurisdiction governing this Note, all sums in excess of those lawfully collectible as interest for the period in question
shall, without further agreement or notice by, between, or to any party hereto, be applied to the reduction of the outstanding
principal balance of this Note immediately upon receipt of such sums by the Holder hereof, with the same force and effect as though
the Company had specifically designated such excess sums to be so applied to the reduction of such outstanding principal balance
and the Holder hereof had agreed to accept such sums as a penalty-free payment of principal; provided, however, that the Holder
of this Note may, at any time and from time to time, elect, by notice in writing to the Company, to waive, reduce, or limit the
collection of any sums in excess of those lawfully collectible as interest rather than accept such sums as a prepayment of the
outstanding principal balance. It is the intention of the parties that the Company does not intend or expect to pay nor does the
Holder intend or expect to charge or collect any interest under this Note greater than the highest non-usurious rate of interest
that may be charged under applicable law.

 

14.          Binding
Effect. This Note shall be binding upon the Company and the successors and assigns of the Company and shall inure to the benefit
of Holder and the successors and assigns of Holder.

 

15.          Severability.
In the event any one or more of the provisions of this Note shall for any reason be held to be invalid, illegal, or unenforceable,
in whole or in part, in any respect, or in the event that any one or more of the provisions of this Note operates or would prospectively
operate to invalidate this Note, then and in any of those events, only such provision or provisions shall be deemed null and void
and shall not affect any other provision of this Note. The remaining provisions of this Note shall remain operative and in full
force and effect and shall in no way be affected, prejudiced, or disturbed thereby.

 

    	6

    	 

    

 

16.          Participations.
Holder may from time to time sell or assign, in whole or in part, or grant participations in this Note and/or the obligations evidenced
hereby, subject, however, to first obtaining the Company’s written consent. The holder of any such sale, assignment or participation,
if the applicable agreement between Holder and such holder so provides, shall be: (a) entitled to all of the rights, obligations
and benefits of Holder (to the extent of such holder’s interest or participation); and (b) deemed to hold and may exercise
the rights of setoff or banker’s lien with respect to any and all obligations of such holder to the Company (to the extent
of such holder’s interest or participation), in each case as fully as though the Company was directly indebted to such holder.

 

17.          Amendments.
The provisions of this Note may be changed only by a written agreement executed by the Company and Holder.

 

[Signature
pages follows] 

 

    	7

    	 

    

 

IN WITNESS WHEREOF,
the Company has caused this Note to be executed on and as of the date set forth above.

 

	 	NUGENE, INC. 
	 	 	 
	 	By:	 
	 	Name:	 
	 	Title:	Chief Executive Officer

 

[ Signature
Page to Promissory Note ]Exhibit 10.6

 

BUSINESS TRANSFER AND INDEMNITY AGREEMENT

 

by
and between 

 

BLING MARKETING,
INC.,

 

a Nevada corporation,

 

and,

 

Dena Kurland

 

Dated:
As of December __, 2014

 

BMI/NuGene Business Transfer-Indemnity

 

    	 

    	 

    

 

BUSINESS TRANSFER AND INDEMNITY AGREEMENT

 

THIS BUSINESS TRANSFER
AND INDEMNITY AGREEMENT (this “Agreement”), dated as of December__, 2014, is entered into by and among Bling
Marketing, Inc., a Nevada corporation (“BMI” or “Company”), Dena Kurland, an individual (“Buyer”),
and is made with reference to the following matters:

 

RECITALS

 

A.           BMI
is engaged in marketing affordable jewelry at wholesale (the “Jewelry Operations”).

 

B.           The
BMI Jewelry Operations are further described in the BMI's most recent quarterly reports on Form 10-Q for the periods ended March
31, 2014, June 30, 2014 and September 30, 2014 as filed with the Securities and Exchange Commission (“SEC”) on May
5, 2014 and August 13, 2013, and October 27, 2014 respectively.

 

C.           
BMI has entered into that certain Agreement and Plan of Merger (the “Merger Agreement”), dated as of December
__, 2014, with NuGene, Inc., a California corporation (“NuGene”), and NG Acquisition, Inc., a California
corporation wholly owned by BMI (“Acquisition Sub”), pursuant to which Acquisition Sub will be merged with and
into NuGene (the “Merger”), with NuGene as the surviving corporation and a wholly-owned subsidiary of BMI.

 

D.           
It is a covenant under the Merger Agreement that upon or following effectiveness of the Merger (the “Merger Closing”
and the date of the Merger Closing, the “Merger Closing Date”) that BMI (i) sell or commit to sell to Buyer
and that Buyer acquire or commits to acquire from BMI all of the Jewelry Operations (inclusive of cash, inventories, accounts
payable, accrued expenses and loan from related party in amount of $22,039 at September 30, 2014), (ii) acquire from the Buyer
all of the shares of BMI owned by Buyer amounting to 15,000,000 shares of common stock (the "Indemnity Shares")
before giving effect to a 15:04 : 1 forward share split in the form of a stock dividend (the "Stock Split"), (iii)
pay to Buyer an aggregate of $350,000 and that (iv) BMI receives or obtains from Buyer indemnities that hold BMI, NuGene and the
shareholders or equity holders of NuGene as of the Closing (the “Existing NuGene Shareholders”) harmless for
any and all liabilities of BMI in existence, arising during, or relating to the period prior to the Closing (such liabilities being,
the “Assumed Liabilities”), excepting those liabilities expressly set forth on Schedule 1 attached hereto which
such liabilities shall remain the sole responsibility of BMI (the “Retained Liabilities”).

 

E.           It
is the express intent of the parties hereto that NuGene and the NuGene Shareholders shall be third-party beneficiaries of Buyers'
obligations in respect of the Indemnified Liabilities under this Agreement as if NuGene and the NeGene Shareholders were parties
to this Agreement.

 

BMI/NuGene Business Transfer-Indemnity

 

    	 

    	 

    

 

NOW, THEREFORE, in
consideration of the mutual promises and covenants set forth herein and for such other good and valuable consideration, the adequacy
and receipt of which are hereby acknowledged, the parties hereby agree as follows:

 

ARTICLE I

DEFINITIONS

 

1.1           Specific
Definitions. When used in this Agreement, the following terms shall have the following meanings:

 

“Affiliate”
shall mean, with respect to any Person (i) a Person directly or indirectly controlling, controlled by or under, control with
such Person, (ii) a Person owning or controlling 10% or more of the outstanding voting securities of such Person or (iii) an
officer, director, general partner, member or manager of such Person, or a member of the immediate family of an officer, director,
general partner, member or manager of such Person. When the Affiliate is an officer, director, partner or manager of such Person
or a member of the immediate family of an officer, director, general partner, member or manager of such Person, any other Person
for which the Affiliate acts in that capacity shall also be considered an Affiliate. For these purposes, control means the possession,
direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the
ownership of voting securities, as trustee or executor, by contract or otherwise.

 

“Agreement”
shall mean this Business Transfer And Indemnity Agreement, including all schedules thereto, as the same may hereafter be amended,
modified or supplemented from time to time.

 

“Applicable Law”
shall mean, with respect to any Person, any domestic or foreign, Federal, state or local statute, law, ordinance, rule, administrative
interpretation, regulation, order, writ, injunction, directive, judgment, decree or other requirement of any Authority applicable
to such Person or any of its Affiliates or ERISA Affiliates or any of their respective properties, assets, officers, directors,
general partners, managers, employees, consultants or agents (in connection with such officer’s, director’s, general
partner’s, manager’s, employee’s, consultant’s or agent’s activities on behalf of such Person or
any of its Affiliates or ERISA Affiliates).

 

“Assumed Liabilities”
shall have the meaning specified in paragraph D of Recitals.

 

“Authority”
shall mean any governmental, regulatory or administrative body, agency or authority, any court or tribunal of judicial authority,
any arbitrator or any public, private or industry regulatory authority, whether Federal, state, local or foreign.

 

“Business Day”
shall mean a day other than a Saturday, Sunday or other day on which commercial banks in Los Angeles, California are authorized
or required by Applicable Law to close.

 

“Buyer"
shall have the meaning set forth in the introductory paragraph of this Agreement.

 

NUGENE/BMI

Business Transfer Indemnity Agreement

 

    	2

    	 

    

 

“Buyer Documents”
shall mean this Agreement and all other agreements, instruments and certificates to be executed and delivered by Buyer in connection
with this Agreement.

 

“Closing”
shall mean the consummation of the transactions contemplated in this Agreement.

 

“Closing Date”
shall mean the date upon which the Closing occurs.

 

“Code”
shall mean the Internal Revenue Code of 1986, as the same may hereafter be amended from time to time. Any reference to a specific
section of the Code shall refer to the cited provisions as the same may be subsequently amended from time to time, as well as to
any successor provision(s).

 

“BMI” shall
have the meaning set forth in the introductory paragraph hereof.

 

“BMI Documents”
shall mean this Agreement and all other agreements, instruments and certificates to be executed by BMI in connection with this
Agreement.

 

“BMI Indemnified
Parties” shall have the meaning specified in Section 8.2.

 

“Contracts”
of a Person shall mean all contracts, agreements, warranties, guaranties, indentures, bonds, options, leases, subleases, easements,
mortgages, plans, collective bargaining agreements, licenses, commitments or binding arrangements of any nature whatsoever, express
or implied, written or unwritten, and all amendments thereto, entered into or binding upon that Person or to which any property
of that Person may be subject.

 

“Effective Date
of the Closing” shall have the meaning specified in Section 3.1.

 

“Effective Time”
shall mean 12:01 a.m. Los Angeles time on the Effective Date of the Closing.

 

“Indemnity Shares”
shall have the meaning specified in paragraph D of Recitals.

 

“Jewelry Operations”
shall have the meaning specified in paragraph B of Recitals.

 

“Lien”
shall mean any lien, encumbrance, pledge, mortgage, security interest, lease, charge, conditional sales contract, option, restriction,
reversionary interest, right of first refusal, voting trust arrangement, preemptive right, claim under bailment or storage contract,
easement or any other adverse claim or right whatsoever.

 

“Losses”
shall mean all damages, awards, judgments, assessments, fines, sanctions, penalties, charges, costs, expenses, payments, Taxes,
diminutions in value and other losses, however suffered or characterized, all interest thereon, all costs and expenses of
investigating any claim, lawsuit or arbitration and any appeal therefrom, all actual attorneys’, accountants’ investment
bankers’ and expert witness’ fees incurred in connection therewith, whether or not such claim, lawsuit or arbitration
is ultimately defeated and, subject to ARTICLE VIII, all amounts paid incident to any compromise or settlement of any such
claim, lawsuit or arbitration.

 

NUGENE/BMI

Business Transfer Indemnity Agreement

 

    	3

    	 

    

 

“Merger Closing”
shall have the meaning defined in paragraph D of Recitals.

 

“Merger Closing
Date” shall have the meaning defined in paragraph D of Recitals as set forth above.

 

“Order”
shall mean any decree, order, judgment, writ, award, injunction, rule or consent of or by an Authority.

 

“Person”
shall mean any entity, corporation, company, association, joint venture, joint stock company, partnership, trust, organization,
individual (including personal representatives, executors and heirs of a deceased individual), nation, state, government (including
agencies, branches, departments, bureaus, boards, divisions and instrumentalities thereof), trustee, receiver or liquidator, as
well as any syndicate or group that would be deemed to be a Person under Section 13(d)(3) of the Securities Exchange Act of 1934,
as amended.

 

“Proceeding”
shall have the meaning specified in Section 6.1.

 

“Purchase Price”
shall have the meaning specified in Section 2.2.

 

"Stock Split"
shall have the meaning defined in paragraph D of Recitals as set forth above.

 

“Tax” shall
mean any federal, state, local or foreign tax, charge, fee, levy, deficiency or other assessment of whatever kind or nature (including
without limitation, any net income, gross income, gross receipts, sales, use, value added, ad valorem, transfer, franchise, profits,
license, withholding, payroll, employment, unemployment, excise, estimated, severance, stamp, occupation, real property, personal
property, intangible property, occupancy, recording, minimum, environmental and windfall profits tax, including any liability therefor
as a transferee (including without limitation under Section 6901 of the Code or any similar provision of Applicable Law), as a
result of Treasury Regulation Section 1.1502-6 or any similar provision of Applicable Law, or as a result of any tax sharing or
similar agreement, together with any interest, penalty, addition to tax or additional amount imposed by any Tax Authority. “Taxing”
and Taxable” shall have the correlative meanings.

 

“Transfer Taxes”
shall mean all Taxes (other than Taxes measured on or by net income) incurred or imposed upon Buyer BMI by reason of the transfer
of the Transferred Shares to Buyer pursuant to this Agreement, including sales and use taxes, real property transfer taxes, excise
taxes, and stamp, documentary, filing, recording, permit, license, registration or authorization duties or fees (including penalties
and interest in respect of any of the foregoing).

 

NUGENE/BMI

Business Transfer Indemnity Agreement

 

    	4

    	 

    

 

1.2           Interpretation;
Construction. References in this Agreement to “Articles,” “Sections” and “Schedules,”
shall be to the Articles, Sections and Schedules of this Agreement, unless otherwise specifically provided; where the context or
construction requires, all words applied in the plural shall be deemed to have been used in the singular, and vice versa; the masculine
shall include the feminine and neuter, and vice versa; and the present tense shall include the past and future tense, and vice
versa; the words “herein”, “hereof” and “hereunder” and words of similar import, when used
in this Agreement, shall refer to this Agreement as a whole and not to any particular provision of this Agreement; and except as
otherwise specified in this Agreement, all references in this Agreement (a) to any Person shall be deemed to include such Person’s
permitted heirs, personal representatives, successors and assigns, (b) to any agreement, any document or any other written instrument
shall be a reference to such agreement, document or instrument together with all schedules, attachments and appendices thereto,
and in each case as amended, restated, supplemented or otherwise modified from time to time in accordance with the terms thereof
prior to the Effective Time and (c) to any law, statute or regulation shall be deemed references to such law, statute or regulation
as the same may be supplemented, amended, consolidated, superseded or modified from time to time prior to the Effective Time.

 

ARTICLE II

SALE AND PURCHASE OF EQUITY INTERESTS 

 

2.1           Transfer
of Jewelry Operations . On the terms and subject to the conditions set forth in this Agreement and in reliance
upon the representations and warranties of the parties hereto, at the Closing, BMI shall sell, transfer, convey, assign and deliver
to Buyer, and Buyer shall purchase, acquire and accept from BMI, all of the Jewelry Operations.

 

2.2           Purchase
Price and Other Consideration. In exchange for the Jewelry Operations, Buyer shall (i) assume all liabilities, obligations
and costs of the Jewelry Operations that are owing, existing, contingent, or which have arisen or may have arisen through the date
of this Agreement since inception of the BMI, (ii) indemnify and reimburse the BMI from any and all costs, expense or claims or
other losses incurred by the BMI with respect to any matter of any nature that has or have arisen or may be claimed to have arisen
from the date of the BMI's inception on October 30, 2013 through the Closing Date and (iii) shall transfer and deliver the Indemnity
Shares to the BMI (collectively, the foregoing are the "Jewelry Operations Consideration"). In exchange for the
Jewelry Operations Consideration, BMI shall deliver to the Buyer (i) the Jewelry Operations, together with all assets and liabilities
related thereto, and (ii) $350,000 (the "Purchase Indemnity Consideration") .

 

2.3           Transfer
Taxes. All Transfer Taxes imposed by any Tax Authority with respect to any transaction contemplated by this Agreement (if any)
shall be duly and timely paid by Buyer, who shall also duly and timely file all Tax Returns in connection with such Transfer Taxes.
Buyer shall give a copy of each such Tax Return to BMI for its review with sufficient time for comments prior to filing, and shall
give BMI a copy of such Tax Return as filed, together with proof of payment of the Transfer Tax shown thereon, promptly after filing.

 

ARTICLE III

CLOSING

 

3.1           Time
and Place. The Closing shall take place on the Business Day when all of the conditions precedent to each party’s obligations
hereunder have been satisfied or waived and BMI shall have received the Purchase Price. Notwithstanding the foregoing, the Closing
shall be deemed to be effective following the Merger Closing Date (the “Effective Date of the Closing”).

 

NUGENE/BMI

Business Transfer Indemnity Agreement

 

    	5

    	 

    

 

3.2          Transactions
at the Closing and Post-Closing. At the Closing, the following shall occur:

 

(a)          On
the terms and subject to the conditions of this Agreement, Buyer shall deliver each of the items comprising the Jewelry Operations
Consideration as set forth in Section 2.2 of this Agreement;

 

(b)          BMI
shall deliver assignments and other appropriate documents of transfer to Buyer relating to the Jewelry Operations and shall deliver
the Purchase Indemnity Consideration to the Buyer;

 

(c)          BMI
and Buyer shall deliver, or cause to be delivered, to each other any and all other assignments, documents, instruments and conveyances
as may be reasonably requested to effect the consummation of the transactions contemplated by this Agreement to evidence Buyer’s
interest in and title to the Jewelry Operations and BMI's acquisition of the Indemnity Shares.

 

The foregoing transactions
shall be deemed to occur promptly after the Closing.

 

ARTICLE IV

REPRESENTATIONS AND WARRANTIES OF COMPANY

 

BMI represents and
warrants to Buyer that:

 

4.1          Authority
to Execute and Perform Agreements. BMI has the right, power and authority to
enter into, execute and deliver this Agreement and all other BMI Documents and to transfer, convey and sell to Buyer at the Closing
the Jewelry Operations under the terms of this Agreement.

 

4.2          Due
Authorization; Enforceability. BMI has taken all actions necessary to authorize the execution and delivery of this
Agreement and the performance of the obligations under this Agreement and all other BMI Documents. This Agreement and all other
BMI Documents have been duly and validly executed by BMI and (assuming the due authorization, execution and delivery of Buyer)
constitute the legal, valid and binding obligation of BMI, enforceable against such BMI in accordance with their terms, except
as the same may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar Applicable Laws affecting
creditors’ rights generally or by general equitable principles affecting the enforcement of contracts.

 

4.3          No
Broker. No financial advisor, broker, finder, agent or similar intermediary has acted for or on behalf of BMI in connection
with this Agreement or the transactions contemplated herein, and no financial advisor, broker, finder, agent or similar intermediary
is entitled to any broker’s or finder’s or similar fee or other commission in respect of such transactions based on
any agreement, arrangement or understanding with BMI or any action taken by BMI.

 

NUGENE/BMI

Business Transfer Indemnity Agreement

 

    	6

    	 

    

 

ARTICLE V

REPRESENTATIONS AND WARRANTIES

OF BUYER REGARDING COMPANY AND BMI BUSINESS

 

Buyer, represents and
warrants to BMI, for the benefit of BMI, NuGene and the NuGene Shareholders:

 

5.1          Authority;
Due Authorization.

 

(a)          Authority
to Execute and Perform Agreements. Buyer has all requisite power, authority and approvals required to enter into, execute and
deliver this Agreement and all of the other Buyer Documents and to perform fully Buyer’s obligations hereunder and thereunder.

 

5.2          Due
Authorization; Enforceability. Buyer has taken all individual and corporate actions necessary to authorize Buyer to enter into
and perform fully his obligations under this Agreement and all of the other Buyer Documents to be executed by him and to consummate
the transactions contemplated herein and therein. This Agreement has been duly and validly executed by the Buyer and (assuming
due authorization, execution and delivery by BMI) constitutes the legal, valid and binding obligation of Buyer, enforceable against
each of the Buyer in accordance with its terms, except as the same may be limited by applicable bankruptcy, insolvency, reorganization,
moratorium or similar Applicable Laws affecting creditors’ rights generally or by general equitable principles affecting
the enforcement of contracts.

 

5.3          Merger
Agreement Representations and Warranties. Buyer hereby represents and warrants, for Buyer’s own account, all of the representations
and warranties made by, or in respect of, BMI pursuant to the Merger Agreement, as if such representations and warranties are expressly
set forth herein.

 

5.4         Covenant
of Cooperation. Following the Merger Closing, Buyer will cooperate in good faith, and will assist the Company in connection,
with all year end financial statements, audits, filings with the Securities and Exchange Commission, and BMI’s federal and
state tax returns insofar as they may relate to the operations of the Company through closing of this Agreement.

 

ARTICLE VI

CONDITIONS PRECEDENT TO THE OBLIGATION

OF EACH PARTY TO CLOSE

 

The obligations of
BMI and Buyer to consummate the transactions contemplated herein shall be subject to the fulfillment, at or prior to the Closing,
of each of the conditions set forth below (any of which may be waived by the parties in whole or in part):

 

NUGENE/BMI

Business Transfer Indemnity Agreement

 

    	7

    	 

    

 

6.1          No
Action or Proceeding. The consummation of the transactions contemplated herein shall not violate any Applicable Law.
Further, no temporary restraining Order, preliminary or permanent injunction, cease and desist Order or other legal restraint preventing
the consummation of the transactions contemplated herein, or imposing material damages in respect thereof, shall be in effect,
nor shall there be any action or proceeding pending or threatened by any Person which seeks any of the foregoing or seeks to impose
conditions which would be materially burdensome upon the business of BMI and which presents a substantial risk that the
relief sought will be granted.

 

ARTICLE VII

CONDITIONS PRECEDENT TO THE OBLIGATION

OF BUYER TO CLOSE

 

The obligation of Buyer
to consummate the transactions contemplated herein shall be subject to the fulfillment, at or before the Closing Date, of each
of the conditions set forth below (any of which may be waived by Buyer in whole or in part):

 

7.1          Representations
and Warranties. The representations and warranties of BMI contained in this Agreement and in each other BMI Document
shall have been true and correct when made and shall be true and correct in all material respects on and as of the Closing Date
with the same force and effect as though made on and as of the Closing Date, other than such representations and warranties as
are made as of another specified date, which shall be true and correct as of such date, provided, however, that if any portion
of any representation or warranty is already qualified by materiality, for purposes of determining whether this Section 7.1
has been satisfied, that portion of such representation or warranty as so qualified must be true and correct in all respects. At
the Closing, BMI shall have delivered to Buyer a certificate to such effect signed by an officer of BMI and addressed to Buyer.

 

7.2          Performance
of Covenants. Each obligation of BMI to be performed by BMI on or before the Closing Date pursuant to the terms of this
Agreement and each other BMI Document shall have been duly performed on or before the Closing Date. At the Closing, BMI shall have
delivered to Buyer a certificate to such effect signed by an officer of BMI and addressed to Buyer.

 

ARTICLE VIII

INDEMNIFICATION

 

8.1          Indemnification
by BMI. BMI shall indemnify, defend and hold harmless  Buyer, from and against any and all Losses which may be
incurred or suffered by Buyer and which may arise out of or result from:

 

(a)          any
breach of any representation, warranty, covenant or agreement of the BMI contained in this Agreement and

 

(b)          any
and all actions, suits, proceedings, claims, demands, assessments, judgments, costs and expenses, including, without limitation,
reasonable legal fees and expenses, incurred in enforcing this indemnity and the indemnity obligations of BMI set forth
elsewhere in this Agreement.

 

NUGENE/BMI

Business Transfer Indemnity Agreement

 

    	8

    	 

    

 

Notwithstanding anything
to the contrary contained in this Agreement, BMI’s obligation to indemnify Buyer shall cease immediately upon the Closing.

 

8.2          Indemnification
by Buyer. Buyer shall indemnify, defend and hold harmless (i) BMI, (ii) NuGene, (iii) each of their respective Affiliates,
and (iv) each of their respective stockholders including, without limitation the Existing NuGene Shareholders, members, partners,
directors, officers, managers, employees, agents, attorneys and representatives (collectively, the “BMI Indemnified Parties”),
from and against any and all Losses which may be incurred or suffered by any BMI Indemnified Party and which may arise out of or
result from:

 

(a)          any breach of
any representation, warranty, covenant or agreement of Buyer contained in this Agreement, the Merger Agreement or in any other
BMI Document;

 

(b)          any breach
of any representation, warranty, covenant or agreement of BMI contained in the Merger Agreement;

 

(c)          all
activities, actions and omissions to act of BMI (including for purposes hereof, and BMI’s respective Affiliates, stockholders,
members, partners, directors, officers, managers, employees, agents, attorneys and representatives) arising prior to the Closing,
regardless of whether or not any Loss related to any such activity, action or omission to act shall occur after the Closing; and

 

(d)          any
and all actions, suits, proceedings, claims, demands, assessments, judgments, costs and expenses, including, without limitation,
reasonable legal fees and expenses, incurred in enforcing this indemnity and the indemnity obligations of Buyer set forth elsewhere
in this Agreement.

 

In connection with
the foregoing, Buyer agrees and covenants that, notwithstanding Buyer’s indemnification obligations set forth herein, it
is the intent of the parties hereto that Buyer is and shall continue to be the direct and primary obligor for all of the Assumed
Liabilities and Buyer further agrees and covenants that it shall cause all such Assumed Liabilities to be fully satisfied and discharged
in accordance with their respective terms at no cost to BMI.

 

8.2          Survival
of Representations and Covenants of Buyers . Notwithstanding anything to the contrary contained herein and regardless
of any investigation by any BMI Indemnified Party, BMI, NuGene and the other BMI Indemnified Parties shall have the right to rely
fully upon the representations, warranties, covenants and agreements of the Buyer contained in this Agreement, the Merger Agreement
and in any agreement, instrument or other document delivered by Buyer or any of its representatives in connection with the transactions
contemplated by this Agreement and the Merger Agreement. Each representation, warranty, covenant and agreement of Buyer contained
herein and in the Merger Agreement shall survive the execution and delivery of this Agreement and the Closing, and shall thereafter
terminate and expire when a claim thereon is barred by the applicable statute of limitations (including extensions and waivers
thereof).

 

NUGENE/BMI

Business Transfer Indemnity Agreement

 

    	9

    	 

    

 

ARTICLE IX

TERMINATION; REMEDIES

 

9.1          Termination.
This Agreement may be terminated at any time prior to the Closing:

 

(a)          by
the mutual written consent of the parties hereto; or

 

(b)          by
Buyer, on the one hand, or by BMI, on the other hand, if the Closing shall not have occurred by December [31], 2014; provided,
however, that the right to terminate this Agreement pursuant to this Section 9.1(b) shall not be available
to any party or parties whose failure to fulfill any obligation under this Agreement shall have been the cause of, or shall have
resulted in, the failure of the Closing to occur on or prior to such date; or

 

(c)          by
BMI, upon the breach in any material respect of any of the representations and warranties of Buyer contained herein or the failure
by Buyer to perform and comply in any material respect with any of the agreements and obligations required by this Agreement to
be performed or complied with by Buyer, provided that such breach or failure is not cured within 30 calendar days of Buyer’s
receipt of a written notice from BMI that such a breach or failure has occurred.

 

9.2          Effect
of Termination. In the event of the termination of this Agreement in accordance with Section 9.1, this Agreement
shall become void and have no effect, with no liability on the part of any party or its Affiliates, directors, officers, employees,
stockholders or agents in respect thereof; provided, however that nothing herein shall relieve any party hereto from liability
for any breach of this Agreement.

 

9.3          Attorneys’
Fees. If BMI or Buyer shall bring an action against the other by reason of any alleged breach of any covenant, provision
or condition hereof, or otherwise arising out of this Agreement, the unsuccessful party shall pay to the prevailing party all reasonable
attorneys’ fees and costs actually incurred by the prevailing party, in addition to any other relief to which it may be entitled.

 

ARTICLE X

EXPENSES; CONFIDENTIALITY

 

10.1        Expenses
of Sale. Each of the parties hereto shall bear her or its own direct and indirect expenses incurred in connection with
the negotiation and preparation of this Agreement and the consummation and performance of the transactions contemplated herein
and therein.

 

10.2        Confidentiality.
Except in connection with any dispute between the parties and subject to any obligation to comply with (i) any Applicable
Law (ii) any rule or regulation of any Authority or securities exchange or (iii) any subpoena or other legal process
to make information available to the Persons entitled thereto, whether or not the transactions contemplated herein shall be concluded,
all information obtained by any party about any other, and all of the terms and conditions of this Agreement, shall be kept in
confidence by each party, and each party shall cause its stockholders, directors, officers, managers, employees, agents and attorneys
to hold such information confidential. Notwithstanding the foregoing this Agreement may be disclosed within and filed as an exhibit
to any filing made by the BMI with the SEC.

 

NUGENE/BMI

Business Transfer Indemnity Agreement

 

    	10

    	 

    

 

ARTICLE XI

NOTICES

 

11.1        Notices.
All notices, requests and other communications hereunder shall be in writing and shall be delivered by courier or other means of
personal service (including by means of a nationally recognized courier service or professional messenger service), or sent by
facsimile or mailed first class, postage prepaid, by certified mail, return receipt requested, in all cases, addressed to:

 

If to BMI:

 

Bling Marketing, Inc.

c/o
NuGene, Inc. 

720 Paularino Avenue

Costa Mesa, California 92626

Attention: Chief Executive Officer

  

If to Buyer:

 

Dena Kurland

150 West 46th Street

Suite 5R

New
York, New York 10036

 

 

With a copy (which shall
not constitute notice) to:

 

[           ]

 

All notices, requests
and other communications shall be deemed given on the date of actual receipt, delivery or refusal as evidenced by written receipt,
acknowledgement or other evidence of actual receipt or delivery to the address specified above. In case of service by facsimile,
a copy of such notice shall be personally delivered or sent by registered or certified mail, in the manner set forth above, within
three Business Days thereafter. Any party hereto may from time to time by notice in writing served as set forth above designate
a different address or a different or additional Person to which all such notices or communications thereafter are to be given.

 

NUGENE/BMI

Business Transfer Indemnity Agreement

 

    	11

    	 

    

 

ARTICLE
XII

MISCELLANEOUS

 

12.1        Further
Assurances. Each of the parties shall use its reasonable and diligent best efforts to proceed promptly with the transactions
contemplated herein, to fulfill the conditions precedent for such party’s benefit or to cause the same to be fulfilled and
to execute such further documents and other papers and perform such further acts as may be reasonably required or desirable to
carry out the provisions hereof and the transactions contemplated herein.

 

12.2        Modifications
and Amendments; Waivers and Consents. At any time prior to the Closing Date or termination of this Agreement, Buyer,
on the one hand, and BMI, provided that it has obtained the consent of NuGene, on the other hand, may, by written agreement:

 

(a)          modify
or amend the provisions of this Agreement;

 

(b)          extend
the time for the performance of any of the obligations or other acts of the other parties hereto;

 

(c)          waive
any inaccuracies in the representations and warranties made by the other parties contained in this Agreement or any other agreement
or document delivered pursuant to this Agreement; and/or

 

(d)          waive
compliance with any of the covenants or agreements of the other parties contained in this Agreement. However, no such waiver shall
operate as a waiver of, or estoppel with respect to, any subsequent or other failure. Whenever this Agreement requires or permits
a waiver or consent by or on behalf of any party hereto, such waiver or consent shall be given in writing.

 

12.3        Entire
Agreement. This Agreement (including any Schedules hereto) and the agreements, documents and instruments to be executed
and delivered pursuant hereto or referred to herein are intended to embody the final, complete and exclusive agreement among the
parties with respect to the purchase of the Jewelry Operations and related transactions; are intended to supersede all prior agreements,
understandings and representations written or oral, with respect thereto; and may not be contradicted by evidence of any such prior
or contemporaneous agreement, understanding or representation, whether written or oral.

 

12.4        Governing
Law and Venue.

 

(a)          This
Agreement is to be governed by and construed in accordance with the laws of the State of California applicable to contracts made
and to be performed wholly within the State of California, and without regard to the conflicts of laws principles thereof.

 

(b)          Any
suit brought hereon against Buyer or BMI, whether in contract, tort, equity or otherwise, shall be brought in the state or federal
courts sitting in Los Angeles, California, with the parties hereto hereby waiving any claim or defense that each such forum is
not convenient or proper. Each party hereby agrees that any such court shall have in personam jurisdiction over it, consents to
service of process in any manner authorized by California law, and agrees that a final judgment in any such action or proceeding
shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner specified by law.

 

12.5        Assignment.
This Agreement shall be binding upon, shall inure to the benefit of, and shall be enforceable by the parties hereto and their permitted
successors and assigns.

 

NUGENE/BMI

Business Transfer Indemnity Agreement

 

    	12

    	 

    

 

12.6        Counterparts.
This Agreement may be executed simultaneously in any number of counterparts, each of which shall be deemed an original of the party
or parties who executed such counterpart but all of which together shall constitute one and the same instrument. In making proof
of this Agreement it shall not be necessary to produce or account for more than one counterpart evidencing execution by each party
hereto. Delivery of an executed counterpart of a signature page to this Agreement or any Transaction Document by facsimile or electronically
shall be as effective as delivery of a manually executed counterpart of any such agreement.

 

12.7        Section
Headings. The section headings of this Agreement are for convenience of reference only and shall not be deemed to alter
or affect any provision hereof.

 

12.8        Severability.
In the event that any provision or any part of any provision of this Agreement shall be void or unenforceable for any reason whatsoever,
then such provision shall be stricken and of no force and effect. However, unless such stricken provision goes to the essence of
the consideration bargained for by a party, the remaining provisions of this Agreement shall continue in full force and effect,
and to the extent required, shall be modified to preserve their validity.

 

12.9        No
Third-Party Rights. Except as otherwise set forth in this Agreement, no rights or remedies under or by reason of this
Agreement shall be conferred on any Persons other than the parties hereto and their respective successors and assigns, nor is anything
in this Agreement intended to relieve or discharge the obligation or liability of any third Persons to any party to this Agreement,
nor shall any provision give any third Persons any right of subrogation over or action against any party to this Agreement.

 

12.10      Construction.
The language in all parts of this Agreement shall in all cases be construed simply, according to its fair meaning, and not strictly
for or against any of the parties hereto. Without limitation, there shall be no presumption against any party on the ground that
such party was responsible for drafting this Agreement or any part thereof.

 

12.11      Advice
of Counsel. Each party acknowledges that such party has consulted with or has had the opportunity to consult with and
be represented by independent counsel of such party’s own choice concerning this Agreement, and each party acknowledges that
such party has carefully read and fully understands this Agreement, is fully aware of the contents thereof and its meaning and
legal effect, and has entered into it free from coercion, duress or undue influence.

 

NUGENE/BMI

Business Transfer Indemnity Agreement

 

    	13

    	 

    

  

IN WITNESS WHEREOF,
the parties hereto have duly executed this Agreement as of the day and year first above written.

 

	 	BUYER:
	 	 
	 	 
	 	Dena Kurland
	 	 
	 	COMPANY:
	 	 
	 	BLING MARKETING, INC.,
	 	a Nevada corporation
	 	 
	 	By:	 
	 	 	 
	 	Name:	 
	 	 	 
	 	Title:	 

 

NUGENE/BMI Bus Transfer Indemnity Signature
Page

 

    	 

    	 

    

  

SCHEDULE 1

TO

Jewelry Operations Transfer and Indemnity
Agreement

 

RETAINED LIABILITIES

 

All loans, expenses, taxes, license fees,
liabilities and claims have been assumed by Buyer.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}]]